Trajectories of apoB/apoA-1 ratio, apoB, and apoA-1 over a 25-year period prior to a major adverse cardiovascular event (MACE) or myocardial infarction, for cases and controls, in... حسب Göran Walldius (286838)

الموضوعات:

Benchmarking DFT Accuracy in Predicting O 1s Binding Energies on Metals حسب Elizabeth E. Happel (22391811)

الموضوعات:

Benchmarking DFT Accuracy in Predicting O 1s Binding Energies on Metals حسب Elizabeth E. Happel (22391811)

الموضوعات:

Correlations between various environmental variables and cases of <i>Vibrio vulnificus</i>. حسب Andrea J. Ayala (3120333)

"…The mean WSPD for months when no cases were reported was 3.35 ± 0.02 SE m/s, while the mean WSPD for months when cases where survival was the outcome was a mean of 3.26 ± 0.05 SE m/s, and the mean WSPD for months when death was the outcome was 3.27 ± 0.10 SE m/s. …"

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( حسب Farrokh Habibzadeh (12256529)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases. حسب Simon K. Schnyder (16632244)

Reclassification of breast cancers into molecular subtypes [26]. حسب Anette H. Skjervold (16455810)

Costs and Benefits of Popular <i>P</i>‑Value Correction Methods in Three Models of Quantitative Omic Experiments حسب Steven R. Shuken (14500192)

"…We show how increasing sample size, decreasing variability, or increasing effect size can enable the detection of all true changes while still correcting <i>p</i>-values, and we present basic guidelines for omic experimental design. …"

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Representative cases of the BT474 xenograft model treated with intra-arterial saline injection. حسب Bo Kyu Kim (18501276)

الموضوعات:

Representative cases of the BT474 xenograft model treated with intra-arterial trastuzumab injections. حسب Bo Kyu Kim (18501276)

الموضوعات:

Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values). حسب Willem Kaijser (12872371)

Simulation result (2^nd case, <i>v</i>₁). حسب Tuan Anh Nguyen (121944)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

The notation corresponding to model (26). حسب Sarvar Sadat Kassaei (17081471)

Mean values of “I feel bored” item. حسب Ezel Üsten (16548547)